About danicopan
Complement factor D inhibitor
Used for
- Add-on treatment for adults with paroxysmal nocturnal hemoglobinuria and residual hemolytic anemia despite ravulizumab or eculizumab.
Usual adult dose
Start 150 mg three times daily; may increase to 200 mg three times daily if needed after at least four weeks.
Common side effects
- Headache
- Nausea
- Diarrhea
- Upper respiratory tract infection
Important warnings
- Used with ravulizumab or eculizumab, not as a replacement.
- Increases risk of serious infections, including meningococcal infection; vaccination and monitoring are important.
- Monitor liver tests before and during treatment.
- Do not stop suddenly without medical supervision; hemolysis may worsen.
Pregnancy
Human pregnancy data are insufficient; use only when potential benefit justifies potential risk.
Breastfeeding
It is unknown whether danicopan passes into breast milk; discuss risks and benefits with a clinician.
Interactions
- Strong CYP3A inhibitors can increase danicopan levels.
- Strong CYP3A inducers can reduce danicopan levels.
- Danicopan can affect levels of medicines transported by BCRP, OATP1B1, or OATP1B3.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.